||||||||||SAR443216 / Sanofi [VIRTUAL] SAR443216, a novel trispecific T cell engager with potent T cell-dependent cytotoxicity for HER2-low tumors () - Mar 11, 2021 - Abstract #AACR2021AACR_3276; Finally, in a HER2-low breast cancer xenograft model, SAR443216 also exhibited significant anti-tumor activity in immuno-deficient NSG mice reconstituted with primary human T cells. Thus, SAR443216 represents a promising new drug for cancer patients with HER2-expressing tumors, including those who are currently ineligible for stand-of-care therapy.